Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 1, 2023
Existing Board member Jerry He to replace David Green as Chairman and Chief Executive Officer; David Green to remain on the Board and support transition HOLLISTON, Mass., March 1, 2023 /PRNewswire/ --
-
Jan 12, 2023
Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer. HOLLISTON, Mass., Jan. 12, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...
-
Dec 28, 2022
IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass., Dec. 28, 2022 /PRNewswire/ -- Biostage, Inc....
-
Dec 23, 2022
Biostage expects to initiate patient recruitment in its first clinical trial in early 2023 HOLLISTON, Mass., Dec. 23, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the...
-
Nov 14, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...
-
Nov 10, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Oct 25, 2022
Extends core IP from tubes to patches and from regenerating the esophagus after esophagectomy to treating fistulas and strictures anywhere in the GI tract including the esophagus, stomach and...
-
Aug 8, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...
-
Aug 4, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...
-
Aug 4, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jun 15, 2022
The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the tissue was comparable to adjacent native tissue. HOLLISTON,...
-
May 16, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
May 13, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo...
-
May 10, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Apr 11, 2022
Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass., April 11, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or...
-
Apr 1, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Mar 30, 2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 25, 2022Thursday, Jan. 27. 2-3pm ET via Zoom
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 25, 2022Court holds that Biostage's insurer breached its duty to defend a litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant.
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo...
-
Jan 10, 2022Establishes the basis for a clinical trial in human babies with birth defects in the esophagus.
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial...
Nov 30, 2021New CEO Invests $250,000 in Private Placement and is Appointed as Board ChairmanBiostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial...
-
Nov 15, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
Sep 8, 2021Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing novel organ regeneration technology based its patented Cellframe™ and Cellspan™ technology,...
-
Aug 13, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
-
May 24, 2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today...
